Abbvie inc. (ABBV)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities
Net earnings

8,436

7,882

3,255

4,118

5,360

5,687

7,565

6,449

6,381

5,309

6,648

6,615

6,310

5,953

6,079

5,720

5,476

5,144

2,817

2,084

1,816

1,774

3,712

4,170

4,140

4,128

4,540

5,161

5,360

5,275

0

0

0

Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation

461

464

468

469

474

471

450

446

437

425

442

427

425

425

428

434

430

417

393

385

384

383

385

388

385

388

462

458

477

525

0

0

0

Amortization of intangible assets

1,659

1,600

1,526

1,419

1,355

1,300

1,266

1,214

1,159

1,100

1,018

958

870

764

694

611

516

419

375

348

361

403

408

447

484

509

544

541

581

625

0

0

0

Change in fair value of contingent consideration liabilities

2,994

3,091

2,270

2,185

366

49

511

817

393

626

632

333

313

228

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

460

430

421

421

419

421

428

424

415

365

363

361

356

353

331

317

301

282

272

261

254

241

235

233

231

212

206

194

183

187

0

0

0

Upfront costs and milestones related to collaborations

335

490

691

726

1,155

1,061

1,096

1,073

543

470

135

183

283

280

230

280

178

280

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Devaluation loss related to Venezuela

-

-

-

-

-

-

-

-

-

-

-

-

-

298

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Other, net

-77

-43

255

52

58

-76

-580

-68

-140

-84

9

-450

-373

-390

-446

-168

-302

-489

-479

-889

-730

-434

-330

59

27

-34

-56

-73

-68

-66

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

783

74

-8

-118

226

591

1,034

1,029

1,038

391

105

44

186

71

363

682

451

1,076

1,109

880

883

172

-122

-216

-791

-681

-164

-56

-59

-223

0

0

0

Inventories

210

231

260

323

283

226

155

99

49

-93

185

37

-14

38

-40

274

340

434

669

460

328

203

-50

-91

17

56

190

197

185

203

0

0

0

Prepaid expenses and other assets

-190

-97

-110

50

344

499

522

536

332

118

293

379

287

393

63

-68

-11

-511

-492

-329

-340

220

-162

-75

-211

-459

-133

-269

-182

-90

0

0

0

Accounts payable and other liabilities

-150

-1,121

-1,273

-1,109

93

190

862

967

882

425

232

-1,806

-1,495

-1,187

-800

1,183

1,357

1,503

1,136

433

607

-193

-654

-461

-832

-426

-270

-239

-925

-731

0

0

0

Cash flows from operating activities

14,122

13,324

13,441

13,410

13,799

13,427

12,619

11,366

10,503

9,960

8,917

7,100

7,015

7,041

7,463

8,164

8,078

7,535

4,994

4,625

4,510

3,549

5,372

5,384

5,704

6,267

5,963

6,414

5,938

6,345

0

0

0

Cash flows from investing activities
Acquisition of businesses, net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,488

0

0

0

-

-

-

-

-

-

-

-

688

0

0

0

Acquisitions and investments

792

1,100

671

775

684

736

669

609

617

308

270

230

297

262

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisitions of property and equipment

570

552

512

640

626

638

697

541

553

529

461

448

453

479

510

524

508

532

540

593

620

612

610

563

540

491

435

284

259

333

0

0

0

Purchases of investment securities

402

583

790

1,713

1,719

1,792

1,973

1,476

1,527

2,230

2,633

2,686

4,943

5,315

0

0

0

-

-

-

-

1,169

0

0

0

-

-

-

-

-

-

-

-

Sales and maturities of investment securities

2,131

2,699

2,901

1,715

2,443

2,160

2,817

2,958

2,660

2,793

2,670

2,602

2,770

2,359

1,597

1,993

924

899

0

0

0

-

-

-

-

2,705

2,608

2,598

2,099

1,153

0

0

0

Other

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities

494

596

928

-1,413

-586

-1,006

-522

332

-37

-274

-594

-684

-5,300

-6,074

-6,252

-5,308

-13,521

-12,936

-10,125

-13,154

-1,002

-926

-3,317

-1,997

-1,405

879

550

-292

-727

-2,418

0

0

0

Cash flows from financing activities
Net change in commercial paper borrowings

-499

-699

0

-205

132

299

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of other short-term borrowings

0

3,000

3,000

3,000

3,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in short-term borrowings

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-760

494

-169

-19

459

-251

566

12

-110

-159

-410

-601

0

0

0

-

-

-

-

Repayments of long-term debt and finance lease obligations

-

-

-

-

-

6,035

5,028

3,025

26

25

4,022

4,018

6,016

6,010

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

182

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Dividends paid

6,541

6,366

6,222

6,092

6,031

5,580

5,159

4,724

4,217

4,107

4,010

3,917

3,820

3,717

3,624

3,541

3,432

3,294

3,128

2,951

2,806

2,661

2,628

2,595

2,560

2,555

0

0

0

-

-

-

-

Purchases of treasury stock

652

629

2,685

3,690

11,203

12,014

10,461

9,457

1,946

1,410

2,715

2,716

6,519

6,033

5,467

6,459

7,653

7,586

6,655

5,656

678

665

553

552

552

320

0

0

0

-

-

-

-

Proceeds from the exercise of stock options

16

8

13

14

15

73

106

169

231

254

272

248

276

268

242

223

185

155

191

206

194

232

267

284

341

347

0

0

0

-

-

-

-

Payments of contingent consideration liabilities

216

163

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net transactions with Abbott Laboratories, excluding non-cash items

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-247

-13,285

-10,982

-12,379

-13,504

0

0

0

Other, net

39

35

34

30

-2

14

-10

8

32

21

12

5

12

29

45

32

13

36

44

36

-5

-53

-32

-8

49

-66

-215

-244

-239

-151

0

0

0

Cash flows from financing activities

21,669

18,708

-11,719

-10,362

-17,270

-14,396

-12,499

-14,225

-6,227

-5,512

-6,086

-6,647

-4,503

-3,928

-3,857

-3,542

5,463

5,752

7,301

7,638

-2,946

-3,293

-3,158

-3,052

-3,137

-3,442

-306

2,551

1,725

1,931

0

0

0

Effect of exchange rate changes on cash and equivalents

-40

7

-17

-10

-53

-39

-29

-14

28

29

-9

-8

-28

-338

-359

-387

-370

-300

-666

-795

-796

-577

-153

8

-1

-10

0

0

0

-

-

-

-

Net change in cash and equivalents

36,245

32,635

2,633

1,625

-4,110

-2,014

-431

-2,541

4,267

4,203

2,228

-239

-2,816

-3,299

-3,005

-1,073

-350

51

1,504

-1,686

-234

-1,247

-1,256

343

1,161

3,694

6,214

8,669

6,938

5,874

0

0

0